Abstract:Gene therapy is a promising modality for the treatment of inherited and acquired cardiovascular diseases. The identification of the molecular pathways involved in the pathophysiology of heart failure and other associated cardiac diseases led to encouraging preclinical gene therapy studies in small and large animal models. However, the initial clinical results yielded only modest or no improvement in clinical endpoints. The presence of neutralizing antibodies and cellular immune responses directed against the viral vector and/or the gene-modified cells, the insufficient gene expression levels, and the limited gene transduction efficiencies accounted for the overall limited clinical improvements. Nevertheless, further improvements of the gene delivery technology and a better understanding of the underlying biology fostered renewed interest in gene therapy for heart failure. In particular, improved vectors based on emerging cardiotropic serotypes of the adeno-associated viral vector (AAV) are particularly well suited to coax expression of therapeutic genes in the heart. This led to new clinical trials based on the delivery of the sarcoplasmic reticulum Ca(2+)-ATPase protein (SERCA2a). Though the first clinical results were encouraging, a recent Phase IIb trial did not confirm the beneficial clinical outcomes that were initially reported. New approaches based on S100A1 and adenylate cyclase 6 are also being considered for clinical applications. Emerging paradigms based on the use of miRNA regulation or CRISPR/Cas9-based genome engineering open new therapeutic perspectives for treating cardiovascular diseases by gene therapy. Nevertheless, the continuous improvement of cardiac gene delivery is needed to allow the use of safer and more effective vector doses, ultimately bringing gene therapy for heart failure one step closer to reality.

Gene therapy for cardiovascular diseases in China: basic research

Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects

Nanotechnology-based non-viral vectors for gene delivery in cardiovascular diseases

Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation

Gene Therapy for Cardiovascular Disease: Clinical Perspectives

Non-Viral Gene Delivery Systems for Treatment of Myocardial Infarction: Targeting Strategies and Cardiac Cell Modulation

Gene Editing Therapy for Cardiovascular Diseases

AAV-mediated gene therapy: Advancing cardiovascular disease treatment

Gene Therapy Research in China

State of Gene Therapy for Monogenic Cardiovascular Diseases

The Recent Advances in Cell Delivery Approaches, Biochemical and Engineering Procedures of Cell Therapy Applied to Coronary Heart Disease

Gene- and Cell-Based Therapies for Cardiovascular Diseases: Current Status and Future Directions

Gene and Cell‐based Therapies for Heart Disease

Gene and stem cell therapy for inherited cardiac arrhythmias

Cardiovascular gene therapy for myocardial infarction

Gene therapy of arthritis and orthopaedic disorders: current experimental approaches in China and in Canada.

Research progress of gene therapy for arrhythmias

The Origin, Progress, and Application of Cell‐based Cardiac Regeneration Therapy

CRISPR/CAS9: A promising approach for the research and treatment of cardiovascular diseases

Gene therapy research in Asia

Gene therapy for cardiac diseases: methods, challenges, and future directions